International Journal of Environmental Research and Public Health (MDPI)
2004 | 525,942,120 words
The International Journal of Environmental Research and Public Health (IJERPH) is a peer-reviewed, open-access, transdisciplinary journal published by MDPI. It publishes monthly research covering various areas including global health, behavioral and mental health, environmental science, disease prevention, and health-related quality of life. Affili...
Association between Low-Dose Computed Tomography Results and 1-Year Smoking...
Da-Som Shin
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Hye-Mi Noh
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Hong Ji Song
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Kyung Hee Park
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Young-Gyun Seo
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Yu-Jin Paek
Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea
Download the PDF file of the original publication
Year: 2022 | Doi: 10.3390/ijerph19095510
Copyright (license): Creative Commons Attribution 4.0 International (CC BY 4.0) license.
[Full title: Association between Low-Dose Computed Tomography Results and 1-Year Smoking Cessation in a Residential Smoking Cessation Program]
[[[ p. 1 ]]]
Citation: Shin, D.-S.; Noh, H.-M.; Song, H.J.; Park, K.H.; Seo, Y.-G.; Paek, Y.-J. Association between Low-Dose Computed Tomography Results and 1-Year Smoking Cessation in a Residential Smoking Cessation Program Int. J. Environ Res. Public Health 2022 , 19 , 5510 https://doi.org/10.3390/ijerph 19095510 Academic Editor: David Berrigan Received: 14 March 2022 Accepted: 29 April 2022 Published: 1 May 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations Copyright: © 2022 by the authors Licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) International Journal of Environmental Research and Public Health Article Association between Low-Dose Computed Tomography Results and 1-Year Smoking Cessation in a Residential Smoking Cessation Program Da-Som Shin, Hye-Mi Noh * , Hong Ji Song, Kyung Hee Park, Young-Gyun Seo and Yu-Jin Paek * Department of Family Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Korea; ektha 0602@hallym.or.kr (D.-S.S.); hongji@hallym.or.kr (H.J.S.); beloved@hallym.or.kr (K.H.P.); yg 035@hallym.or.kr (Y.-G.S.) * Correspondence: hyeminoh@hallym.or.kr (H.-M.N.); paek@hallym.or.kr (Y.-J.P.); Tel.: +82-31-380-3805 (H.-M.N.); +82-31-380-3805 (Y.-J.P.) Abstract: The COVID-19 pandemic is a global health threat. Smoking and smoking-related lung diseases are risk factors for severe COVID-19 infection. This study investigated whether low-dose computed tomography (LDCT) scan results affected the success of 1-year smoking cessation. The Gyeonggi Southern Smoking Support Center performed the residential smoking cessation program from January to December 2018. During the program, LDCT was performed on 292 participants; 6 months later, follow-up via telephone or visit was conducted. Among the 179 participants who succeeded in smoking cessation for 6 months, telephone follow-up was conducted to determine whether there was a 12-month continuous smoking cessation. In order to evaluate the association between LDCT results and 12-month continuous abstinence rate (CAR), logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI). The CARs at 6 and 12 months were 61.3% and 31.5%, respectively. Indeterminate or suspicious malignant lung nodules were associated with a higher 12-month CAR (OR, 3.02; 95% CI, 1.15–7.98), whereas psychiatric history was associated with a lower 12-month CAR (OR, 0.06; 95% CI, 0.03–0.15). These results suggest that abnormal lung screening results may encourage smokers to quit smoking Keywords: COVID-19; lung cancer; smoking cessation; tobacco; computed tomography 1. Introduction The COVID-19 pandemic is ongoing worldwide. Although there are inconsistent results on whether smoking increases the risk of COVID-19 infection [ 1 , 2 ], smoking is a risk factor for severe COVID-19 infection and death [ 3 ]. Particularly, patients with smoking-related lung diseases such as chronic pulmonary obstructive disease and lung cancer are more vulnerable to COVID-19 [ 4 ]. The prevalence of smoking among Korean adults decreased to 20.6% in 2020 from 35.1% in 1998 [ 5 ]. However, during the pandemic, the Ministry of Health and Welfare of South Korea stopped public health centers that provided national smoking cessation services such as face-to-face counseling to prevent the spreading of COVID-19. The sales of conventional cigarettes increased from 3063 in 2019 to 3209 million packs in 2020. Furthermore, the number of smokers participating in national smoking cessation services rapidly decreased during the pandemic to 89,283 in the first half of 2020 from 358,966 in 2019 [ 6 ]. Lung cancer is the leading cause of cancer-related deaths, accounting for approximately 1.8 million deaths worldwide [ 7 ]. The incidence rate of lung cancer in Korea ranked third in the overall cancer incidence rates in 2018. For older adults aged 65 years and above, the incidence rate of lung cancer is higher than that of younger adults, ranking first in men and second in women [ 8 ]. In addition, the number of deaths from lung cancer has continuously increased from 13,246 in 2004 to 17,980 in 2017 among Koreans [ 9 ]. Int. J. Environ. Res. Public Health 2022 , 19 , 5510. https://doi.org/10.3390/ijerph 19095510 https://www.mdpi.com/journal/ijerph
[[[ p. 2 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 2 of 10 Lung cancer screening is advantageous for the early detection and treatment of lung cancer. In the National Lung Screening Test (NLST) conducted in the United States, screening tests were conducted on high-risk lung cancer groups (aged 55–74 years) with a history of smoking for more than 30 pack-years. A comparison between the group examined with low-dose computed tomography (LDCT) and the control group examined with simple chest radiography showed 20% and 7% reductions in lung cancer mortality and all-cause mortality in the LDCT group, respectively [ 10 ]. In the Netherlands and Belgium, the Nederlands Leuvens Screening ONderzoek (NELSON) trial showed that lung cancer mortality rates decreased by 24% for men and 33% for women in participants (aged 50–74 years) who underwent volume CT screening compared to those without screening [ 11 ]. Smoking cessation is the most effective strategy for preventing lung cancer-related deaths [ 12 ]. Beyond the potential benefits of early detection of lung cancer in CT screening, smoking cessation counseling has been considered an essential factor in lung cancer screening programs in the United States [ 13 ]. Abnormal results of lung cancer screening tests, such as suspicious malignancy or other pulmonary diseases, can be used to encourage smoking cessation as a “teachable moment”. To date, results regarding the effect of CT screening results on smoking cessation have been inconsistent. Several studies have reported that participants with abnormal findings on LDCT had a higher success rate of smoking cessation than those with normal LDCT [ 14 – 16 ]. However, some studies have shown no difference in the prolonged abstinence rate between the group with normal findings and the group with abnormal findings on LDCT [ 17 , 18 ]. In South Korea, the national lung cancer screening has been conducted since 2019 However, no Korean study has evaluated the association between lung cancer screening results and smoking cessation. In addition, since 2015, the Korean government has funded residential smoking cessation programs that are held for 5 days for participants with a smoking duration ≥ 20 years in 18 regional tobacco control centers. As one of the regional tobacco control centers, we operate smoking cessation programs and evaluate lung screening tests by LDCT for participants. In our previous study, we identified factors associated with 6-month smoking cessation [ 19 ]. This study aimed to (1) investigate the rate of 12-month continuous smoking abstinence in a residential smoking cessation program and (2) estimate whether the results of LDCT scans affect the success of smoking cessation 2. Materials and Methods 2.1. Study Participants This study included participants who had completed a 5-day smoking cessation camp program conducted by the Gyeonggi Southern Smoking Support Center between January 2018 and December 2018. According to the National Tobacco Control Center of the Ministry of Health and Welfare of Korea, the criteria for selecting participants were as follows: (1) participants with a smoking history of 20 years or more who have attempted smoking cessation more than twice and/or (2) those with chronic diseases (e.g., dyslipidemia, diabetes mellitus, and hypertension). Of the 313 participants in the smoking cessation camp 2018, we included 292 participants who underwent LDCT as the study population. Of 292 participants, 179 were successful in quitting smoking for 6 months For the 179 participants who succeeded in smoking cessation for 6 months, telephone counseling was conducted to confirm whether smoking cessation continued for 1 year All participants provided written informed consent prior to participating in this study. The study protocol was approved by the Institutional Review Board of Hallym University Sacred Heart Hospital (approval number: 2019-01-023) 2.2. Measurements The demographic and socioeconomic characteristics of the participants were collected Data on age, sex, education, alcohol consumption, exercise, chronic comorbidities (hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, cerebrovascular disease,
[[[ p. 3 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 3 of 10 cancer, and psychiatric disorders), information about smoking (smoking duration, cigarettes per day, results of the Fagerström Test for Nicotine Dependence [FTND]), and smoking cessation medications were collected. For lung cancer screening, LDCT was evaluated in all participants. LDCT was performed by an experienced radiologist. Pulmonary nodules were divided into four categories: (1) normal, (2) benign nodule, (3) indeterminate nodule requiring follow-up scan, and (4) suspicious malignancy. In addition, abnormal findings, such as emphysema, interstitial lung disease, extrapulmonary neoplasm, and coronary calcification, were noted in the CT reports 2.3. Intervention and Follow-Up As mentioned in the previous study, a multidisciplinary team (physicians, nurses, and counselors) of the regional tobacco control center provided the 5-day residential smoking cessation program. Physicians prescribed smoking cessation medications (e.g., varenicline, bupropion, or nicotine replacement therapy [NRT]) to participants. The program consisted of lectures on smoking cessation education, intensive psychological counseling, and counseling on the results of LDCT screening [ 19 ]. Telephone follow-up or follow-up visit at 2, 4, 6, 12, 18, and 24 weeks after the residential smoking cessation program was conducted. Continuous abstinence was evaluated biochemically via urine cotinine (COT) test, exhaledair carbon monoxide (CO) level test (visit), or self-reports (telephone). The cut-off value for urine COT was 20 ng/mL (COT urine rapid test), and the cut-off value for exhaled CO was 5 ppm. Non-responders for >2 months were considered to have a smoking relapse Among the 179 participants who succeeded in smoking cessation for 6 months, followup was conducted only by telephone interview to determine whether there was 12-month continuous smoking cessation (continuous abstinence rate [CAR]) by asking the following question: “After participating in the smoking cessation camp, have you maintained smoking cessation continuously for 12 months?”. In total, 92 participants reported that they continuously succeeded in smoking cessation for 12 months, 54 failed, and 33 did not respond to telephone counseling. We considered non-respondents to be failures (Figure 1 ). Int. J. Environ. Res. Public Health 2022 , 19 , x 4 of 10 Figure 1. Flowchart of study subjects. 2.4. Statistical Analysis Continuous variables were compared using a t-test, and categorical variables were compared using Fisher’s exact test and the chi-squared test. Multivariate logistic regression analysis was used to obtain the odds ratio (OR) and 95% confidence interval (CI) to investigate the predictors of 6- and 12-months smoking cessation. Variables that were significantly different between ex-smoker and smoking relapse groups were included in the models. We adjusted for age and sex in Model 1, and Model 2 included all significant univariable predictors. For all tests, the Statistical Package for the Social Sciences version 23.0 (IBM Co., Armonk, NY, USA) was used. Statistical significance was set at a p -value < 0.05 3. Results Table 1 shows the characteristics of the study participants according to 6- and 12- month smoking cessation. The success rates at 6 and 12 months were 61.3% and 31.5%, respectively. A comparison of success rates by sex showed that both the 6-month CARs (62.6% vs. 45.5%) and the 12-month CARs (33% vs. 13.6%) were higher in men than in women. Those who quit for 6 months had a larger proportion of higher education, regular exercise, history of dyslipidemia and cerebrovascular disease, absence of psychiatric disease, lower smoking pack-years, and FTND score. Those who quit for 12 months had a higher proportion of history of cerebrovascular disease and absence of psychiatric disease (Table 1). Table 1. Characteristics of study subjects according to 6 and 12 months of smoking cessation success. Variables 6 Months p -Value 12 Months p -Value Success Fail Success Fail 179 (61.3) 113 (38.7) 92 (31.5) 200 (68.5) Age (yr, mean ± SD) 55.38 (10.46) 55.02 (11.16) 0.779 53.87 (9.67) 55.87 (11.14) 0.139 Sex 0.113 0.092 Men 169 (94.4) 101 (89.4) 89 (96.7) 181 (90.5) Figure 1. Flowchart of study subjects.
[[[ p. 4 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 4 of 10 2.4. Statistical Analysis Continuous variables were compared using a t-test, and categorical variables were compared using Fisher’s exact test and the chi-squared test. Multivariate logistic regression analysis was used to obtain the odds ratio (OR) and 95% confidence interval (CI) to investigate the predictors of 6- and 12-months smoking cessation. Variables that were significantly different between ex-smoker and smoking relapse groups were included in the models We adjusted for age and sex in Model 1, and Model 2 included all significant univariable predictors. For all tests, the Statistical Package for the Social Sciences version 23.0 (IBM Co., Armonk, NY, USA) was used. Statistical significance was set at a p -value < 0.05 3. Results Table 1 shows the characteristics of the study participants according to 6- and 12-month smoking cessation. The success rates at 6 and 12 months were 61.3% and 31.5%, respectively A comparison of success rates by sex showed that both the 6-month CARs (62.6% vs. 45.5%) and the 12-month CARs (33% vs. 13.6%) were higher in men than in women. Those who quit for 6 months had a larger proportion of higher education, regular exercise, history of dyslipidemia and cerebrovascular disease, absence of psychiatric disease, lower smoking pack-years, and FTND score. Those who quit for 12 months had a higher proportion of history of cerebrovascular disease and absence of psychiatric disease (Table 1 ). Table 1. Characteristics of study subjects according to 6 and 12 months of smoking cessation success Variables 6 Months p -Value 12 Months p -Value Success Fail Success Fail 179 (61.3) 113 (38.7) 92 (31.5) 200 (68.5) Age (yr, mean ± SD) 55.38 (10.46) 55.02 (11.16) 0.779 53.87 (9.67) 55.87 (11.14) 0.139 Sex 0.113 0.092 Men 169 (94.4) 101 (89.4) 89 (96.7) 181 (90.5) Women 10 (5.6) 12 (10.6) 3 (3.3) 19 (9.5) Education level 0.022 0.451 Middle school or less 14 (7.8) 21 (18.6) 8 (8.7) 27 (13.5) High school 70 (39.1) 38 (33.6) 37 (40.2) 71 (35.5) College or beyond 95 (53.1) 54 (47.8) 47 (51.1) 102 (51.0) Alcohol consumption 0.777 0.433 Yes 92 (51.4) 60 (53.1) 51 (55.4) 101 (50.5) Regular Exercise 0.023 0.571 Yes 69 (38.5) 29 (25.7) 33 (35.9) 65 (32.5) Hypertension 52 (29.1) 40 (35.4) 0.255 27 (29.3) 65 (32.5) 0.590 Diabetes Mellitus 32 (17.9) 22 (19.5) 0.733 14 (15.2) 40 (20.0) 0.328 Dyslipidemia 53 (29.6) 20 (17.7) 0.022 29 (31.5) 44 (22.0) 0.081 Coronary artery disease 13 (7.3) 12 (10.6) 0.318 8 (8.7) 17 (8.5) 0.956 Cerebrovascular disease 11 (6.1) 1 (0.9) 0.033 8 (8.7) 4 (2.0) 0.011 Cancer 12 (6.7) 7 (6.2) 0.864 6 (6.5) 13 (6.5) 0.994 Psychiatric disease 37 (20.7) 91 (80.5) <0.001 7 (7.6) 121 (60.5) <0.001 Smoking pack-years (mean ± SD) 35.84 (14.19) 40.92 (19.99) 0.020 35.79 (11.54) 38.73 (18.72) 0.102 FTND (a) score 0.016 0.665 0 3 (1.7) 2 (1.8) 1 (1.1) 4 (2.0) Mild [ 1 – 3 ] 65 (36.3) 22 (19.5) 26 (28.3) 61 (30.5) Moderate [ 4 – 6 ] 68 (38.0) 53 (46.9) 43 (46.7) 78 (39.0) Severe [ 7 – 10 ] 43 (24.0) 36 (31.9) 22 (23.9) 57 (28.5) Pharmacotherapy 0.275 0.233 No 8 (4.5) 5 (4.4) 1 (1.1) 12 (6.0) NRT (b) 67 (37.4) 49 (43.4) 41 (44.6) 75 (37.5)
[[[ p. 5 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 5 of 10 Table 1. Cont Variables 6 Months p -Value 12 Months p -Value Success Fail Success Fail Varenicline 6 (3.4) 8 (7.1) 4 (4.3) 10 (5.0) Varenicline + short term NRT (b) 98 (54.7) 51 (45.1) 46 (50.0) 103 (51.5) Data are presented as the mean ± standard deviation or as the frequency (percentage) (a) FTND: Fagerstrom Test for Nicotine dependence, (b) NRT: Nicotine replacement therapy Table 2 shows the results of the LDCT screening of the study participants. Of 30 participants who had indeterminate or suspicious nodules, 29 participants (96.7%) had indeterminate nodules, and 1 participant (3.3%) had a suspicious nodule. The 6-month CARs and the 12-month CARs were the participants with normal (59.6% and 27.6%), benign nodules (55.7% and 25.5%), and indeterminate or suspicious malignancy nodules (90% and 73.3%) Both 6- and 12-month ex-smokers had a higher proportion of indeterminate or suspicious malignant lung nodules on LDCT than participants who failed smoking cessation ( p = 0.001 and p < 0.001). Moreover, 6-month ex-smokers had a higher proportion of interstitial lung disease and coronary artery calcification in LDCT than participants who failed smoking cessation ( p = 0.046 and p = 0.026). Furthermore, 12-month ex-smokers had a lower proportion of emphysema on LDCT than participants who failed smoking cessation, despite being statistically insignificant ( p = 0.057) Table 2. The results of low-dose CT screening of study subjects Variables 6 Months p -Value 12 Months p -Value Success Fail Success Fail 179 (61.3) 113 (38.7) 92 (31.5) 200 (68.5) Low-dose computed tomography Nodule 0.001 <0.001 Negative 93 (52.0) 63 (55.8) 43 (46.7) 113 (56.5) Benign 59 (33.0) 47 (41.6) 27 (29.3) 79 (39.5) Indeterminate or suspicious malignancy 27 (15.1) 3 (2.7) 22 (23.9) 8 (4.0) Emphysema 49 (27.4) 36 (32.1) 0.384 20 (21.7) 65 (32.7) 0.057 Interstitial lung disease 7 (3.9) 0 0.046 2 (2.2) 5 (2.5) 1.000 Extrapulmonary neoplasm 7 (3.9) 1 (0.9) 0.157 4 (4.3) 4 (2.0) 0.266 Coronary artery calcification 56 (31.3) 22 (19.5) 0.026 20 (21.7) 58 (29.0) 0.193 Data are presented as the frequency (percentage) Table 3 shows the multivariate logistic regression analysis of predictors for 6-month smoking cessation. Higher educational level (OR, 4.37; 95% CI, 1.36–14.08) and performing regular exercise (OR, 2.41; 95% CI, 1.22–4.76) were associated with a higher 6-month CAR. Having a psychiatric disease (OR, 0.06; 95% CI, 0.03–0.12) was associated with a lower 6-month CAR. A higher FTND score was associated with a lower 6-month CAR in Model 1 (OR 0.88; 95% CI, 0.80–0.98); however, it lost statistical significance in Model 2 (OR 0.88; 95% CI 0.77–1.00) Table 4 shows the multivariate logistic regression analysis of the predictors of 12-month smoking cessation. Indeterminate or suspicious malignant lung nodules on LDCT were associated with a higher 12-month CAR (OR, 3.02; 95% CI, 1.15–7.98). The psychiatric disease was associated with a lower 12-month CAR (OR, 0.06; 95% CI, 0.03–0.15).
[[[ p. 6 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 6 of 10 Table 3. Multivariable logistic regression analysis of predictors for 6 months smoking cessation Variables Unadjusted Model 1 Model 2 OR 95% CI OR 95% CI OR 95% CI Age 1.00 (0.98–1.03) 1.00 (0.9–1.03) 1.03 (1.00–1.06) Sex Men 1 1 1 Women 0.50 (0.21–1.19) 0.50 (0.21–1.19) 1.67 (0.55–5.16) Education level Middle school or less 1 1 1 High school 2.76 (1.26–6.05) 3.16 (1.36–7.33) 4.39 (1.36–14.14) College or beyond 2.64 (1.21–5.61) 3.12 (1.34–7.28) 4.37 (1.36–14.08) Regular Exercise Yes 1.82 (1.08–3.05) 1.79 (1.07–3.02) 2.41 (1.22–4.76) Dyslipidemia 1.96 (1.10–3.49) 2.01 (1.12–3.61) 1.77 (0.80–3.96) Cerebrovascular disease 7.33 (0.93–57.60) 6.90 (0.88–54.40) 8.50 (0.75–96.11) Psychiatric disease 0.06 (0.04–0.11) 0.06 (0.03–0.11) 0.06 (0.03–0.12) FTND (a) score 0.98 (0.97–0.99) 0.88 (0.80–0.98) 0.88 (0.77–1.00) Low-dose computed tomography Nodule Negative 1 1 1 Benign 0.85 (0.52–1.40) 0.80 (0.48–1.35) 0.79 (0.40–1.57) Indeterminate or suspicious malignancy 6.10 (1.77–20.96) 5.67 (1.64–19.59) 1.31 (0.34–5.12) Coronary artery calcification 1.88 (1.07–3.31) 1.94 (1.08–3.50) 1.91 (0.89–4.12) Data are presented as odds ratio (95% confidence interval), (a) FTND: Fagerstrom Test for Nicotine dependence, Model 1: adjusted for age and sex, Model 2 adjusted for age, sex, education level, regular exercise, dyslipidemia, cerebrovascular disease, psychiatric disease, FTND score, lung nodule, coronary artery calcification Table 4. Multivariable logistic regression analysis of predictors for 12 months smoking cessation Variables Unadjusted Model 1 Model 2 OR 95% CI OR 95% CI OR 95% CI Age 0.98 (0.96–1.01) 0.98 (0.96–1.01) 0.99 (0.96–1.24) Sex Men 1 1 1 Women 0.32 (0.09–1.11) 0.33 (0.09–1.04) 0.60 (0.14–2.62) Cerebrovascular disease 4.67 (1.37–15.92) 4.82 (1.40–16.68) 3.24 (0.77–13.63) Psychiatric disease 0.05 (0.02–0.12) 0.06 (0.02–0.13) 0.06 (0.03–0.15) FTND (a) score 0.93 (0.90–1.10) 1.01 (0.91–1.13) 1.09 (0.96–1.24) Nodule Negative 1 1 1 Benign 0.90 (0.51–1.57) 0.99 (0.55–1.78) 1.03 (0.53–2.01) Indeterminate or suspicious malignancy 7.23 (2.99–17.46) 7.25 (2.95–17.81) 3.02 (1.15–7.98) Emphysema 0.57 (0.32–1.02) 0.58 (0.32–1.07) 0.58 (0.28–1.19) Data are presented as odds ratio (95% confidence interval), (a) FTND: Fagerstrom Test for Nicotine dependence, Model 1: adjusted for age and sex, Model 2 adjusted for age, sex, cerebrovascular disease, psychiatric disease, FTND score, lung nodule, emphysema 4. Discussion In this study, the 12-month CAR of the participants in the residential smoking cessation camp was 31.5%. In baseline LDCT, indeterminate or suspicious malignant lung nodules were associated with a higher 12-month CAR; however, they were not associated with a 6-month CAR. Psychiatric disease in the study participants was associated with lower 6-and 12-month CARs.
[[[ p. 7 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 7 of 10 Several studies have investigated the effect of CT screening results on smoking cessation; however, they have shown mixed results. Some studies have reported that the quit rate was higher in participants with abnormal findings on LDCT than in those with normal findings, which is in line with our results [ 14 – 16 , 20 ]. A study that used data from the NLST showed that participants with abnormal findings in the LDCT had a higher success rate of smoking cessation than those with normal findings; in particular, more severe findings or changes in LDCT had stronger associations with smoking cessation [ 14 ]. In a recent study, Clark et al. reported that false-positive screening results were associated with increased abstinence and less relapse at the 5-year follow-up [ 15 ]. Moreover, in the UK Lung Cancer Screening Trial, participants who had abnormal findings that required additional clinical investigation had a higher quit rate than those with negative results [ 16 ]. A study from the Danish Lung Cancer Screening trial reported that 1-year quit rates were higher in participants with abnormal CT findings who required a repeat scan 3 months later [ 20 ]. In contrast, a study from the NELSON trial showed that the results of LDCT had no statistically significant effect on smoking abstinence in males. However, they found a statistically insignificant increase in the abstinence rate for one or more indeterminate test results compared to only negative test results [ 17 ]. In this study, of 30 study participants who had indeterminate or suspicious nodules, 29 participants (96.7%) had indeterminate nodules, and 1 participant (3.3%) had a suspicious nodule. Smoking cessation of participants who have indeterminate nodules could contribute to preventing lung cancer. Furthermore, in lung cancer patients, smoking increases the risk of recurrence and death after cancer treatment [ 21 ]. All smokers who undergo lung screening should be encouraged to quit smoking Unlike previous lung cancer screening programs that provided brief smoking cessation counseling to participants, we provided smoking cessation counseling with pharmacological treatment for up to 6 months after the completion of residential smoking cessation programs. Therefore, in our study, it was difficult to clearly distinguish the effect of intensive smoking cessation counseling during this period and the effect of smoking cessation due to LDCT findings. In this study, the abnormal LDCT findings (indeterminate or suspicious malignant lung nodules) were not associated with the 6-month CAR but were associated with a higher 12-month CAR As with other notable findings of this study, participants with emphysema on LDCT tended to have a lower 12-month CAR. It is possible that the participants did not recognize the harmfulness of emphysema compared to lung nodules [ 22 ], and physicians unconsciously more focused on the health risks of cancer to patients compared to those of emphysema. In the recent COVID-19 pandemic, populations with underlying lung diseases are at risk of severe COVID-19 progression and death [ 4 ]. Therefore, providing motivation for smoking cessation through a sufficient explanation of abnormal screening findings is important In this study, psychiatric history was inversely associated with both the 6- and 12-month CARs. Previous studies have shown that the smoking cessation rate of patients with mental illness is lower than that of the population without mental illness [ 23 , 24 ]. Mental illness is related to various smoking-related risk factors, such as poverty, low education, and unemployment. In addition, the lack of proper recognition of the health effects of smoking, lack of will and confidence, and restrictions on access to smoking cessation programs might be obstacles to quitting smoking among psychiatric patients [ 25 ]. In addition, we found that higher education levels and performing regular exercise were associated with higher 6-month smoking cessation rates. Some studies have investigated the association between educational level and smoking status. A nationwide Japanese survey reported that the adjusted prevalence ratio of current smoking was higher in junior high school graduates than in university graduates [ 26 ]. Smokers with a higher educational level had a higher rate of smoking cessation [ 27 ]. This was because education on the harmful effects of smoking was possible for highly educated people.
[[[ p. 8 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 8 of 10 Regular exercise may decrease symptoms of cigarette withdrawal and cravings. Some observational studies have reported that physical activity helps with smoking cessation and reduces relapse [ 28 , 29 ]. However, a systematic review, including randomized controlled trials, showed that exercise plus smoking cessation support did not improve long-term abstinence for at least 6 months compared to smoking cessation support alone [ 30 ]. A recent randomized controlled trial reported that telephone-delivered exercise counseling with usual care (behavioral counseling and NRT) failed to improve smoking abstinence rates compared to usual care alone; however, they found that more intervention calls successfully delivered were associated with a lower probability of smoking [ 31 ]. Further clinical trials are required to clarify whether exercise improves the success rate of smoking cessation The strengths of our study are as follows [ 1 ]. This is the first study in South Korea to examine the association between lung screening results and smoking cessation. Our study adds to the evidence regarding the association between CT screening results and smoking habits. Further [ 2 ], we presented a wide range of information on demographic factors, lifestyle factors, and comorbidities of the study participants. In addition, our results remained significant after adjusting for these covariates. Despite its strengths, this study has some limitations. First, 1-year smoking cessation was determined through telephone interview (self-report) and was not biologically confirmed through examination. Second, we selected participants from smoking cessation camps conducted in one regional tobacco control center, and a relatively small number of subjects and shorter follow-up period is one of the limitations. Third, because we considered unresponsive participants as relapses, there may have been a misclassification bias. Fourth, there was no direct comparison group who did not undergo lung screening in a residential smoking cessation program. In terms of indirect comparison with smokers who visited the Korea National Health Insurance Service smoking cessation program 2016 in primary care clinics, their 6- and 12-month CARs were 39% and 23.4% [ 32 ], which were relatively lower quit rates compared to our results 5. Conclusions The 12-month CAR of participants in the residential smoking cessation program was 31.5%. Indeterminate or suspicious malignant lung nodules were associated with a higher 12-month CAR, whereas a psychiatric history was associated with a lower 12-month CAR. These results suggest that the explanation of abnormal lung screening results for smokers can encourage smoking cessation as a “teachable moment”. Especially in the recent COVID- 19 pandemic, smokers and patients with smoking-related diseases are at risk of severe COVID-19 infection. In this regard, smoking cessation counseling is essential in lung screening programs Author Contributions: Conceptualization, D.-S.S. and H.-M.N.; Methodology, H.-M.N. and Y.-J.P.; Formal Analysis, H.-M.N.; Data Curation, D.-S.S. and H.-M.N.; Writing—Original Draft Preparation, D.-S.S. and H.-M.N.; Writing—Review and Editing, H.J.S., K.H.P. and Y.-G.S.; Supervision, H.J.S., K.H.P. and Y.-J.P.; Funding acquisition, Y.-J.P. All authors have read and agreed to the published version of the manuscript Funding: This study was supported by Health Promotion Fund, Ministry of Health and Welfare, Republic of Korea (2019-008) Institutional Review Board Statement: The study protocol was approved by the Institutional Review Board of Hallym University Sacred Heart Hospital (approval number: 2019-01-023) Informed Consent Statement: Written informed consent has been obtained from the patient (s) to publish this paper Data Availability Statement: The raw data were generated at the Korea Health Promotion Institute Derived data supporting the findings of this study are available from the corresponding authors on reasonable request Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the study design, data collection, analysis, data interpretation, or in the decision to publish the results.
[[[ p. 9 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 9 of 10 References 1 Patanavanich, R.; Glantz, S.A. Smoking Is Associated with COVID-19 Progression: A Meta-analysis Nicotine Tob Res 2020 , 22 , 1653–1656 [ CrossRef ] [ PubMed ] 2 Simons, D.; Shahab, L.; Brown, J.; Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 7) Addiction 2021 , 116 , 1319–1368. [ CrossRef ] [ PubMed ] 3 Clift, A.K.; von Ende, A.; Tan, P.S.; Sallis, H.M.; Lindson, N.; Coupland, C.A.C.; Munaf ò , M.R.; Aveyard, P.; Hippisley-Cox, J.; Hopewell, J.C. Smoking and COVID-19 outcomes: An observational and Mendelian randomisation study using the UK Biobank cohort Thorax 2022 , 77 , 65–73. [ CrossRef ] 4 Aveyard, P.; Gao, M.; Lindson, N.; Hartmann-Boyce, J.; Watkinson, P.; Young, D.; Coupland, C.A.C.; Tan, P.S.; Clift, A.K.; Harrison, D.; et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: A population cohort study Lancet Respir. Med 2021 , 9 , 909–923. [ CrossRef ] 5 Korea Disease Control and Prevention Agency. Korea National Health and Nutrition Examination Survey: Current Smoking Rate Trend, 1998–2020. Available online: https://kosis.kr/statHtml/statHtml.do?orgId=177&tblId=DT_11702_N 001&conn_path=I 2 (accessed on 13 March 2022) 6 Kim, J.Y.; Lee, S.K. Impact of the COVID-19 Pandemic on Tobacco Sales and National Smoking Cessation Services in Korea Int. J Environ. Res. Public Health 2022 , 19 , 5000. [ CrossRef ] 7 Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin 2021 , 71 , 209–249. [ CrossRef ] [ PubMed ] 8 Hong, S.; Won, Y.J.; Lee, J.J.; Jung, K.W.; Kong, H.J.; Im, J.S.; Seo, H.G.; Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018 Cancer Res. Treat 2021 , 53 , 301–315 [ CrossRef ] [ PubMed ] 9 Lee, J.G.; Kim, H.C.; Choi, C.M. Recent Trends of Lung Cancer in Korea Tuberc. Respir. Dis 2021 , 84 , 89–95. [ CrossRef ] [ PubMed ] 10 National Lung Screening Trial Research Team; Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening N. Engl. J. Med 2011 , 365 , 395–409. [ CrossRef ] [ PubMed ] 11 de Koning, H.J.; van der Aalst, C.M.; de Jong, P.A.; Scholten, E.T.; Nackaerts, K.; Heuvelmans, M.A.; Lammers, J.J.; Weenink, C.; Yousaf-Khan, U.; Horeweg, N.; et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial N. Engl J. Med 2020 , 382 , 503–513. [ CrossRef ] [ PubMed ] 12 Warren, G.W.; Cummings, K.M. Tobacco and Lung Cancer: Risks, Trends, and Outcomes in Patients with Cancer Am. Soc. Clin Oncol. Educ. Book 2013 , 33 , 359–364. [ CrossRef ] [ PubMed ] 13 US Preventive Services Task Force; Krist, A.H.; Davidson, K.W.; Mangione, C.M.; Barry, M.J.; Cabana, M.; Caughey, A.B.; Davis, E.M.; Donahue, K.E.; Doubeni, C.A.; et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement JAMA 2021 , 325 , 962–970. [ CrossRef ] [ PubMed ] 14 Tammemägi, M.C.; Berg, C.D.; Riley, T.L.; Cunningham, C.R.; Taylor, K.L. Impact of Lung Cancer Screening Results on Smoking Cessation J. Natl. Cancer Inst 2014 , 106 , dju 084. [ CrossRef ] [ PubMed ] 15 Clark, M.A.; Gorelick, J.J.; Sicks, J.D.; Park, E.R.; Graham, A.L.; Abrams, D.B.; Gareen, I.F. The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Screening Trial: Implications for Public Health Nicotine Tob. Res 2016 , 18 , 17–24. [ CrossRef ] [ PubMed ] 16 Brain, K.; Carter, B.; Lifford, K.J.; Burke, O.; Devaraj, A.; Baldwin, D.R.; Duffy, S.; Field, J.K. Impact of Low-Dose CT Screening on Smoking Cessation among High-Risk Participants in the UK Lung Cancer Screening Trial Thorax 2017 , 72 , 912–918. [ CrossRef ] 17 van der Aalst, C.M.; van Klaveren, R.J.; van den Bergh, K.A.; Willemsen, M.C.; de Koning, H.J. The Impact of a Lung Cancer Computed Tomography Screening Result on Smoking Abstinence Eur. Respir. J 2011 , 37 , 1466–1473. [ CrossRef ] 18 Anderson, C.M.; Yip, R.; Henschke, C.I.; Yankelevitz, D.F.; Ostroff, J.S.; Burns, D.M. Smoking Cessation and Relapse during a Lung Cancer Screening Program Cancer Epidemiol. Biomark. Prev 2009 , 18 , 3476–3483. [ CrossRef ] 19 Park, M.J.; Seo, Y.G.; Noh, H.M.; Kim, Y.; Yoon, J.L.; Paek, Y.J. Effectiveness of National Residential Smoking Cessation Program Int. J. Environ. Res. Public Health 2021 , 18 , 9901. [ CrossRef ] 20 Ashraf, H.; Tønnesen, P.; Holst Pedersen, J.; Dirksen, A.; Thorsen, H.; Døssing, M. Effect of CT Screening on Smoking Habits at 1-Year Follow-Up in the Danish Lung Cancer Screening Trial (DLCST) Thorax 2009 , 64 , 388–392. [ CrossRef ] 21 Cataldo, J.K.; Dubey, S.; Prochaska, J.J. Smoking cessation: An integral part of lung cancer treatment Oncology 2010 , 78 , 289–301 [ CrossRef ] 22 Szalontai, K.; G é mes, N.; Fur á k, J.; Varga, T.; Neuperger, P.; Balog, J.; Pusk á s, L.G.; Szebeni, G.J. Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer J. Clin. Med 2021 , 10 , 2889. [ CrossRef ] [ PubMed ] 23 Lasser, K.; Boyd, J.W.; Woolhandler, S.; Himmelstein, D.U.; McCormick, D.; Bor, D.H. Smoking and Mental Illness: A Population- Based Prevalence Study JAMA 2000 , 284 , 2606–2610. [ CrossRef ] [ PubMed ] 24 Lawrence, D.; Mitrou, F.; Zubrick, S.R. Non-Specific Psychological Distress, Smoking Status and Smoking Cessation: United States National Health Interview Survey 2005 BMC Public Health 2011 , 11 , 256. [ CrossRef ] [ PubMed ]
[[[ p. 10 ]]]
Int. J. Environ. Res. Public Health 2022 , 19 , 5510 10 of 10 25 Cook, B.L.; Wayne, G.F.; Kafali, E.N.; Liu, Z.; Shu, C.; Flores, M. Trends in Smoking among Adults with Mental Illness and Association between Mental Health Treatment and Smoking Cessation JAMA 2014 , 311 , 172–182. [ CrossRef ] [ PubMed ] 26 Tomioka, K.; Kurumatani, N.; Saeki, K. The Association between Education and Smoking Prevalence, Independent of Occupation: A Nationally Representative Survey in Japan J. Epidemiol 2020 , 30 , 136–142. [ CrossRef ] 27 Wetter, D.W.; Cofta-Gunn, L.; Irvin, J.E.; Fouladi, R.T.; Wright, K.; Daza, P.; Mazas, C.; Cinciripini, P.M.; Gritz, E.R. What Accounts for the Association of Education and Smoking Cessation? Prev. Med 2005 , 40 , 452–460. [ CrossRef ] [ PubMed ] 28 Nagaya, T.; Yoshida, H.; Takahashi, H.; Kawai, M. Cigarette Smoking Weakens Exercise Habits in Healthy Men Nicotine Tob. Res 2007 , 9 , 1027–1032. [ CrossRef ] 29 Bernard, P.; Ninot, G.; Guillaume, S.; Fond, G.; Courtet, P.; Christine Picot, M.; Quantin, X. Physical Activity as a Protective Factor in Relapse Following Smoking Cessation in Participants with a Depressive Disorder Am. J. Addict 2012 , 21 , 348–355. [ CrossRef ] 30 Ussher, M.H.; Faulkner, G.E.J.; Angus, K.; Hartmann-Boyce, J.; Taylor, A.H. Exercise Interventions for Smoking Cessation Cochrane Database Syst. Rev 2019 , 2019 , CD 002295. [ CrossRef ] 31 Maddison, R.; Roberts, V.; McRobbie, H.; Bullen, C.; Prapavessis, H.; Glover, M.; Jiang, Y.; Brown, P.; Leung, W.; Taylor, S.; et al. Exercise Counseling to Enhance Smoking Cessation Outcomes: The Fit 2 Quit Randomized Controlled Trial Ann. Behav. Med 2014 , 48 , 194–204. [ CrossRef ] 32 Paek, Y.J.; Choi, J.K.; Lee, E.S.; Jo, M.W. Smoking cessation services provided by the National Health Insurance Service J. Korean Med. Assoc 2018 , 61 , 157–162. [ CrossRef ]
Other Environmental Sciences Concepts:
Discover the significance of concepts within the article: ‘Association between Low-Dose Computed Tomography Results and 1-Year Smoking...’. Further sources in the context of Environmental Sciences might help you critically compare this page with similair documents:
Tobacco, Supervision, Public health, Higher education, Regular exercise, South Korea, Early detection, Observational study, Smoking cessation, COVID 19, COVID-19 Pandemic, Institutional review board, Cerebrovascular disease, Smoking habit, Mental illness, Odds ratio, Confidence interval, Conflicts of interest, Interstitial lung disease, Computed tomography, Lung cancer, Cigarette smoking, Respiratory disease, Pulmonary disease, Nicotine Replacement Therapy, Multidisciplinary team, Smoking history, Multivariate logistic regression analysis, Mental health treatment, Smoking, Smoking status, Psychiatric history, Smoking prevalence, Harmful Effect, Cancer statistics, All-cause mortality, Logistic regression analysis, Cancer incidence rate, Chronic comorbidities, Smoking cessation program, Ministry of Health, Smoking Cessation Counseling, Cigarettes per day, Pack year, Informed consent statement, Exercise intervention, Data availability statement, Cancer-related death, Republic of Korea, Statistical Package for the Social Science, Fagerstrom Test for Nicotine Dependence, Early detection and treatment, Exercise habit, Smoking pack-year, Conventional cigarette, Exercise counseling, Formal analysis, National Health Interview, Lung nodule, Review and editing, Data curation, Funding acquisition, Lung cancer screening, Lung cancer mortality, Smoking cessation medications, Screening for lung cancer, National lung screening trial, Severe COVID-19 infection, Smoking abstinence, Smoking cessation outcomes, Smoking and mental illness, Telephone interview, Telephone follow-up, Pulmonary nodules, Korean government, Korean adults, Original draft preparation, Lung cancer treatment, Telephone counseling, International Journal of Environmental Research and Public Health, Ministry of Health and Welfare, Demographic factor, Lifestyle Factor, UK Biobank Cohort, COVID-19 outcome.
